Full View

CD25 expression could be a prognostic marker of bexarotene monotherapy for cutaneous T‐cell lymphomas

J Yamamoto, K Ohuchi, R Amagai, Y Roh… - Skin Health and …, 2023 - Wiley Online Library
Bexarotene is often administered to phototherapy‐resistant early cutaneous T‐cell
lymphoma (CTCL) patients as one of the first‐line therapies in real‐world practice. Since …
被引用次数：1 相关文章

CD25 expression could be a prognostic marker of bexarotene monotherapy for cutaneous T-cell lymphomas

J Yamamoto, K Ohuchi, R Amagai… - Skin Health and …, 2023 - tohoku.elsevierpure.com
Bexarotene is often administered to phototherapy-resistant early cutaneous T-cell lymphoma
(CTCL) patients as one of the first-line therapies in real-world practice. Since bexarotene …

CD25 expression could be a prognostic marker of bexarotene monotherapy for cutaneous T-cell lymphomas

J Yamamoto, K Ohuchi, R Amagai… - Skin health and …, 2023 - pubmed.ncbi.nlm.nih.gov
Bexarotene is often administered to phototherapy-resistant early cutaneous T-cell lymphoma
(CTCL) patients as one of the first-line therapies in real-world practice. Since bexarotene …
[HTML] nih.gov

[HTML][HTML] CD25 expression could be a prognostic marker of bexarotene monotherapy for cutaneous T‐cell lymphomas

J Yamamoto, K Ohuchi, R Amagai, Y Roh… - Skin Health and …, 2023 - ncbi.nlm.nih.gov
Bexarotene is often administered to phototherapy‐resistant early cutaneous T‐cell
lymphoma (CTCL) patients as one of the first‐line therapies in real‐world practice. Since …

CD25 expression could be a prognostic marker of bexarotene monotherapy for cutaneous T‐cell lymphomas

J Yamamoto, K Ohuchi, R Amagai, Y Roh… - Skin Health and …, 2023 - europepmc.org
Bexarotene is often administered to phototherapy‐resistant early cutaneous T‐cell
lymphoma (CTCL) patients as one of the first‐line therapies in real‐world practice. Since …